Chembio Diagnostics Supports Recent USPSTF Routine Testing Recommendations
MEDFORD, N.Y., May 2, 2013 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc.
(Nasdaq:CEMI), a leader in point-of-care diagnostic tests for infectious
diseases, today announced the Company's support for the U.S. Preventive
Services Task (USPSTF) new recommendations for HIV testing of all adults aged
15-65, regardless of their risk, as published on April 29, 2013 and printed in
the Annals of Internal Medicine.
The new guidelines from the USPSTF, a government-backed panel of doctors and
scientists, now align with longstanding recommendations by the U.S. Centers
for Disease Control and Prevention for testing of all adults aged 15 to 65,
regardless of their risk.
Guidelines issued by the USPSTF in 2005 had recommended HIV screening for
high-risk individuals. Experts said the change will likely trigger coverage
for the tests as a preventive service under the Affordable Care Act. Under
President Barack Obama's healthcare law, insurers are required to cover
preventive services that are recommended by the task force.
"We fully support the new USPSTF HIV testing recommendations, as they should
help to lower overall health care costs by the early identification of those
infected.Early diagnosis helps decrease the spread of these infectious
diseases and promotes early access to care, which reduces the need for more
costly late-stage treatments," said Lawrence Siebert, President and Chief
Executive Officer of Chembio Diagnostics, Inc. "As a result of the
recommendations, it is expected that more individuals will get tested and
learn their HIV status. We believe our current and in-the-pipeline rapid,
point-of-care diagnostic testing products for the detection of HIV, as well as
our tests for other infections that can be related to these, such as Syphilis,
will serve important roles in achieving the goals of the recommendations."
About Chembio Diagnostics
Chembio Diagnostics, Inc. develops, manufactures, licenses and markets
proprietary rapid diagnostic tests in the growing $10 billion point-of-care
testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests
are marketed in the U.S. by Alere, Inc. (formerly, Inverness Medical
Innovations, Inc.). Chembio markets its HIV STAT-PAK^® line of rapid HIV tests
internationally to government and donor-funded programs directly and through
distributors. Chembio has developed a patented point-of-care test platform
technology, the Dual Path Platform (DPP^®) technology, which has significant
advantages over lateral-flow technologies.This technology is providing
Chembio with a significant pipeline of business opportunities for the
development and manufacture of new products based on DPP®. Headquartered in
Medford, NY, with approximately 170 employees, Chembio is licensed by the U.S.
Food and Drug Administration (FDA) as well as the U. S. Department of
Agriculture (USDA), and is certified for the global market under the
International Standards Organization (ISO) directive 13.485.
Statements contained herein that are not historical facts may be
forward-looking statements within the meaning of the Securities Act of 1933,
as amended.Forward-looking statements include statements regarding the
intent, belief or current expectations of the Company and its management.Such
statements are estimates only.Such statements reflect management's current
views, are based on certain assumptions and involve risks and
uncertainties.Actual results, events, or performance may differ materially
from the above forward-looking statements due to a number of important
factors, and will be dependent upon a variety of factors, including, but not
limited to Chembio's ability to obtain additional financing and to obtain
regulatory approvals in a timely manner, as well as the demand for Chembio's
products.Chembio undertakes no obligation to publicly update these
forward-looking statements to reflect events or circumstances that occur after
the date hereof or to reflect any change in Chembio's expectations with regard
to these forward-looking statements or the occurrence of unanticipated
events.Factors that may impact Chembio's success are more fully disclosed in
Chembio's most recent public filings with the U.S. Securities and Exchange
CONTACT: Chembio Diagnostics
(631) 924-1135, ext. 125
Anne Marie Fields
Press spacebar to pause and continue. Press esc to stop.